Avances en inmunoterapia y terapia regenerativa: herramientas y soluciones para la transición desde la investigación hacia la clínica
En esta jornada abordaremos herramientas para inmunoterapia (CAR-T/CAR-NK) y medios especializados para cultivo de células madre mesenquimales con aplicaciones terapéuticas. Soluciones completas para una transición fluida desde la investigación hasta la implementación clínica (medios y reactivos con grado GMP).
¿Te animas?
¡No lo dudes y apúntate ya a estas sesiones gratuitas! Recuerda que debes registrarte de forma independiente en cada una de las charlas de tu interés. ¡Gracias por acompañarnos!
Nuestros ponentes:
Diwas Srivastava
PhD, Product Manager for Cell and Gene Therapy at Takara Bio Europe
Diwas Srivastava holds a PhD in Cancer Biology and completed a postdoc in Viral Immunity. He has a background in cellular biology and immunology and has been a Product Manager for Cell and Gene Therapy at Takara Bio Europe for the past 1.5 years. Specializing in T-cell immunotherapy workflows, he focuses on developing and marketing innovative tools for lentiviral transduction, T-cell expansion, and gene delivery, bridging scientific research with clinical applications.
Growth Factors Group
Vall d'Hebron Institut Oncològic (VHIO)
This research group led by Joaquín Arribas focuses on the resistance mechanisms against targeted therapies and how to overcome this limitation. Their extensive work has lead to the generation and characterisation of different CAR against specific tumor-related antigens, and the development of Antibody-Drug-Conjugates against p95HER2
Karthi Rajamani
Market strategy manager for drug discovery at Takara
Karthi Rajamani is a Market strategy manager for drug discovery at Takara Bio Europe, where she plays a pivotal role in translating cutting-edge research into innovative, market-ready products. With a strong academic background in stem cell research, Karthi has leveraged her education to advance in the industry, combining her scientific knowledge with a passion for innovation. At Takara Bio, she is committed to driving forward impactful solutions that bridge the gap between research and commercialization, helping to shape the future of biotech.
Agenda
10h-11h
Powering T-Cell Immunotherapy: Takara Bio’s Solutions from Discovery to Clinic
Diwas Srivastava, PhD, Product Manager for Cell and Gene Therapy at Takara Bio Europe
Diwas will walk through the T-cell therapy workflow and explore how Takara Bio’s viral portfolio supports each critical step of the immunotherapy process. Covering everything from cloning the gene of interest and packaging lentiviruses to efficient transduction and T-cell expansion, this talk will provide valuable insights for everyone—whether you are a PhD student optimizing experiments at the bench, a researcher advancing translational studies, or a scientist working at the forefront of clinical applications.
11.30h-12h
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors
Growth Factors Group, Vall d'Hebron Institut Oncològic (VHIO)
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors.
12.30h-13h
Tackling Mesenchymal Stem Cell Challenges: Advanced Solutions for Success
Karthi Rajamani, Market strategy manager for drug discovery at Takara Bio Europe.
As the field of regenerative medicine continues to evolve, Mesenchymal Stem Cell Challenges (MSCs) have emerged as a powerful tool for therapeutic applications, with their extracellular vesicles (EVs) opening new frontiers in drug delivery and regenerative treatments. In this session, Karthi Rajamani (Market strategy manager for drug discovery at Takara Bio Europe) will guide us through:
- The therapeutic potential of MSCs – how they are being used in cell therapy and the exciting applications of their EVs.
- Critical quality attributes for clinical success – ensuring the safety, efficacy, and reproducibility of MSC-based therapies.
- Scaling up production – strategies for efficient MSC expansion in both 2D and 3D culture systems.
- Optimizing EV production – key considerations for generating high-quality EVs from MSCs for clinical and research applications.
Whether you’re a researcher, biotech innovator, or industry professional, this webinar will provide valuable insights into the future of MSC-based therapies.